Customers: Republican Clinical Hospital Kazan
Contractors: Angiolain (Angioline) Product: Angiolain: Left atrial eye occluderProject date: 2020/05 - 2020/11
|
2020: Left atrial eye occluder implantation
On December 21, 2020, it became known that the clinical use of the left atrial eye occluder, developed by Angiolain, began in Russia.
Use began at once in two Russian clinics. Occluder was implanted in 5 patients of the Republican Clinical Hospital in Kazan and 2 patients in the clinic of the Bashkir State Medical University in Ufa. All procedures were successful thanks to the support of colleagues from other clinical centers with extensive experience in implantation of such devices. Doctors from Kazan were assisted by doctors from Krasnoyarsk, and doctors in Ufa were instructed by colleagues from Novosibirsk.
I especially want to note the command work of the operational teams in Kazan and Ufa. Occluder implantation is a technically complex procedure that requires the coordinated work of endascular surgeons, anesthesiologists and ultrasound specialists. They all did well, said the Medical Director of Angiolain, Dr. Oleg Volkov.
|
The occluder has the form of a dome made of a nickel-titanium alloy (nitinol) with a membrane shell made of a permeable biocompatible material. The product is intended for occlusion (closure) of left atrium eye in order to prevent ischemic stroke in patients with atrial flicker. arrhythmia This disease is an important problem. health care The prevalence rate of atrial fibrillation is about 0.4% in the general population and increases with age, reaching more than 6% among patients over 80 years old. Patients with atrial fibrillation have an increased risk formations of blood clots in the left atrial ear that can cause ischemic stroke. For the prevention of stroke, such a patient shows a constant intake of anticoagulants. However, those with contraindications to prescribing anticoagulants may be shown to implant the left atrial eye occluder.
The appearance of domestic occluder allows providing high-quality high-tech medical care to a large number of patients in need, - concluded Dr. Volkov.
|